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Abstract 
 
Colorectal cancer (CRC) is the fourth most incident neoplasia worldwide. The 
etiological factors and pathogenic mechanisms underlying the CRC development appear 
to be complex and heterogeneous. The majority of CRC cases occur sporadically, arising 
through the sequential accumulation of multiple genetic and/or epigenetic alterations 
involving genes that regulate cell growth and differentiation. Several molecular pathways 
have been described, such as the chromosomal instability (CIN), the microsatellite 
instability (MSI), and the CpG island methylator phenotype (CIMP) pathways. Despite all 
the knowledge concerning sporadic CRC, the significance of these changes is far from 
complete.  
Recently, germline and sporadic mutations in the polymerase, epsilon, catalytic 
subunit (POLE) gene have been reported in a small subset of microsatellite stable and 
hypermutated CRCs. The POLE gene encodes the proofreading subunit of the 
polymerase epsilon, one of the three DNA polymerases essential to DNA replication. 
These mutations affect the proofreading activity of the enzyme, leading to 
misincorporation of bases during DNA replication. 
The aim of this work was to search for somatic mutations in the POLE gene in 
order to evaluate its role in colorectal carcinogenesis, namely in metastatic CRC (mCRC). 
For that, we performed Sanger sequencing in tumor DNA samples from 307 mCRCs. 
Microsatellite instability and BRAF p.Val600Glu mutation analyses were performed in all 
tumors harboring POLE mutations in order to better characterize these tumors. 
Three heterozygous mutations were found in two tumors, the c.857C>G, 
p.Pro286Arg, the c.901G>A, p.Asp301Asn, and the c.1376C>T, p.Ser459Phe. Of these 
mutations two were described as mutation hotspots, the p.Pro286Arg (the most common 
somatic POLE mutation) and the p.Ser459Phe. These mutations appear to alter the 
normal function of the protein, decreasing the proofreading activity. The BRAF 
p.Val600Glu mutation was not detected in any of these two cases, whereas we observed 
that one tumor was microsatellite stable and the other tumor had low microsatellite 
instability. 
We can conclude that POLE mutations exist but are rare in mCRC. The 
consequences of POLE mutations in colorectal carcinogenesis are not yet completely 
defined and further studies are needed to understand the clinical implications of the POLE 
mutations. 
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Resumo 
 
O cancro colo-retal (CCR) é a quarta neoplasia mais incidente em todo o mundo. 
Os fatores etiológicos e mecanismos subjacentes ao seu desenvolvimento são 
complexos e heterogéneos. A maioria dos casos de CCR ocorrem esporadicamente, 
surgindo através da acumulação sequencial de várias alterações genéticas e/ou 
epigenéticas que envolvem genes que regulam o crescimento e diferenciação celular. 
Foram descritas várias vias de carcinogénese, tais como a via de instabilidade 
cromossómica (CIN), a via da instabilidade de microssatélites (MSI) e a via do fenótipo 
das ilhas CpG metiladas (CpG island methylator phenotype - CIMP). Apesar dos avanços 
na compreensão das vias de carcinogénese do CCR esporádico, o significado destas 
alterações ainda não está completamente compreendido. 
Recentemente, foram descritas mutações germinativas e somáticas no gene 
polymerase, epsilon, catalytic subunit (POLE) num pequeno grupo de CCRs com fenótipo 
de hipermutabilidade e sem instabilidade de microssatélites ou com baixa instabilidade de 
microssatélites. Este gene codifica a subunidade proofreading da polimerase epsilon, 
uma das três polimerases necessárias à replicação do DNA. As mutações descritas 
interferem com as capacidades de proofreading da enzima, conduzindo a uma incorreta 
incorporação de bases durante a replicação do DNA.  
O objetivo deste trabalho foi avaliar o papel das mutações somáticas no gene 
POLE na carcinogénese colo-retal, nomeadamente no CCR metastático (CCRm). Para tal 
procedeu-se à pesquisa de mutações no gene POLE, através de sequenciação de 
Sanger em 307 amostras tumorais de doentes com CCRm. Nos tumores que 
apresentavam mutações no gene POLE procedeu-se também à análise da mutação 
p.Val600Glu do gene BRAF e à análise da instabilidade de microssatélites, com o intuito 
de melhor caraterizar estes tumores.   
Foram identificadas três mutações no gene POLE em dois tumores, a c.857C>G, 
p.Pro286Arg, a c.901G>A, p.Asp301Asn, e a c.1376C>T, p.Ser459Phe. Destas 
mutações, duas estão descritas como hotspots, a p.Pro286Arg (a mutação somática mais 
comum) e a p.Ser459Phe. Estas mutações parecem alterar a função normal da proteína, 
diminuindo a sua atividade proofreading. No nosso estudo observamos que ambos os 
tumores não apresentavam a mutação p.Val600Glu no gene BRAF, um tumor não 
apresentava instabilidade de microssatélites e outro apresentava baixa instabilidade de 
microssatélites.  
 
Resumo 
 
30 
 
Podemos concluir que as mutações no gene POLE existem mas são raras no 
CCRm. Dado o limitado conhecimento do papel destas na carcinogénese colo-retal, são 
necessários estudos adicionais para compreender as suas implicações clínicas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.   Introduction 
 
 
 
 
 
 
Introduction 
 
33 
 
I. Introduction  
 
Colorectal cancer (CRC) remains as one of the most common cancers worldwide. 
The etiological factors and pathogenic mechanisms underlying CRC development appear 
to be complex and heterogeneous. This disease arises through the sequential 
accumulation of multiple genetic and/or epigenetic alterations involving genes that 
regulate cell growth and differentiation. The majority of CRC cases occur sporadically and 
several crucial gene defects in sporadic CRC have been identified. Despite the enormous 
progress in defining some of the common genetic and epigenetic alterations, it is essential 
to further elucidate the molecular heterogeneity of sporadic CRC. 
 
1. Epidemiology  
 
Colorectal cancer is one of the major causes of morbidity and mortality throughout 
the world and accounts for over 9% of all cancer cases diagnosed in 2012 (1 360 602 
cases). Worldwide, in 2012, CRC was the fourth most common cancer in both genders, 
preceded by breast, prostate and lung cancers, with an estimated age-standardized rate 
(ASR) incidence of 17.2/100 000. It was the third most common cancer in men, with an 
estimated ASR incidence of 20.6/100 000 and the second in women with an estimated 
ASR incidence of 14.3/100 000 (figure 1A). Colorectal cancer is not uniformly common 
throughout the world, presenting a large geographic difference in the global distribution, 
with almost 55% of the cases occurring in more developed regions (figure 2). However, 
mortality is lower, with 693 881 deaths, 8.5% of the total, being the fourth most common 
cause of cancer death, preceded by lung, liver and stomach cancer, with an estimated 
ASR mortality of 8.4/100 000. Concerning gender, CRC was the fourth most common 
cause of cancer-related death in men and the third in women, with an estimated ASR 
mortality of 10.0/100 000 and of 6.9/100 000, respectively. Colorectal cancer death rates 
have been decreasing in several western countries, in part due to improving treatment, 
increased awareness and early detection (Ferlay et al., 2013). 
Incidence rates of CRC in Europe are very similar to those described in the world. 
According to Globocan, in 2012, CRC was the third most common type of cancer in both 
genders with an estimated ASR incidence of 29.5/100 000, accounting for 13.1% (447 136 
cases) of all new cancer cases. In women it was the second most incident cancer, with an 
estimated ASR incidence of 23.6/100 000, and the third most common in men with an 
estimated ASR incidence of 37.3/100 000 (Ferlay et al., 2013). The main difference, 
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however, is that in Europe CRC is considered the second cause of cancer-related death, 
accounting for 214 866 deaths (12.2%) with an estimated ASR mortality of 12.5/100 000 
in both genders (figure 1B). Regarding gender, CRC was the third most common cause of 
death from cancer in men and the second in women, with an estimated ASR mortality of 
11.6/100 000 and of 9.9/100 000, respectively (Ferlay et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Estimated age-standardized incidence and mortality rates of CRC for male and female, in A) World, 
B) Europe and C) Portugal. ASR: age-standardized rates (Ferlay et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Estimated age-standardized incidence and mortality rates, per 100,000, of CRC, for male and 
female, in the world (Ferlay et al., 2013). 
  
In terms of CRC incidence and mortality, Portugal follows the same patterns of 
Europe, where CRC is a growing problem, with an estimated ASR incidence of 31.7/100 
000, accounting for 14.5% (7 129 cases) of all new cancers diagnosed in 2012. Data 
A) B) C) 
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analysis by gender, demonstrated that CRC has the second highest incidence in both 
sexes, after prostate cancer in male, with an estimated ASR incidence of 41.8/100 000 
and breast cancer in female, with an estimated ASR incidence of 23.6/100 000. Relative 
to mortality, CRC was the second most common cause of death from cancer with an 
estimated ASR mortality of 13.6/100 000, accounting for 15.7% (3 797 deaths). 
Considering gender, while in men CRC is the second cause of cancer-related deaths with 
an estimated ASR mortality of 19.0/100 000, in women it is the third, with an estimated 
ASR mortality of 9.4/100 000 (figure 1C) (Ferlay et al., 2013).  
 
2. Etiologic factors 
 
Several risk factors are associated with the incidence of CRC. Although the exact 
cause of CRC is not known, there are some factors that increase the risk of developing 
the disease (Rasool et al., 2013). Colorectal cancer is extensively considered to be an 
environmental disease, caused by a wide range of cultural, social, and lifestyle factors. As 
such, CRC is one of the cancers for which modifiable causes may be identified and a 
proportion of cases are theoretically preventable (Haggar et al., 2009; Stegeman et al., 
2013).   
The colon is constantly exposed to the substances we ingest and to the by-
products of ingestion. Although the role of diet in the pathogenesis of CRC has long been 
speculated, their relation is unclear (Haggar et al., 2009, Moore et al., 2011). Diets high in 
fat, particularly saturated animal fat, red and processed meat and low intake of fiber, fruits, 
vegetables, and whole grains has also been implicated in the development of CRC (Boyle 
and Leon, 2002; Haggar et al., 2009; Moore et al., 2011; Vargas and Thompson, 2012). 
Moreover, excessive alcohol consumption, tobacco and obesity, associated with low 
physical activity, also has a possible role in colorectal carcinogenesis (Moore et al., 2011; 
Vargas and Thompson, 2012). There are other risk factors that have lack of consistent 
evidence, such as calcium, vitamin D and folate intake, nonsteroidal anti-inflammatory 
drugs, and hormone replacement therapy (Moore et al., 2011; Vargas and Thompson, 
2012). 
In addition, there are the nonmodifiable risk factors, namely, age, and personal 
history of bowel disease (Haggar et al., 2009; Stegeman et al., 2013). Younger adults can 
develop CRC, but more than 90% of CRC cases occur in people aged 50 or older (Haggar 
et al., 2009). The risk of developing CRC is also increased in individuals with history of 
adenomas, CRC and inflammatory bowel disease, such as ulcerative colitis and Crohn's 
disease (Haggar et al., 2009; Moore et al., 2011).  
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Although most of the CRCs occur without a family history or a predisposing illness, 
approximately 30% of all CRC cases have a familial basis (Haggar et al., 2009; 
Kheirelseid et al., 2013). These are probably caused by genetic alterations not yet 
identified or due to common multifactorial factors (Al-Sohaily et al., 2012). Approximately 
10% of all CRC cases occur in the setting of an established familial genetic syndrome, 
which results from germline inheritance of a mutation in a highly penetrant cancer 
susceptibility gene (Kheirelseid et al., 2013). The most common syndromes identified so 
far are Lynch syndrome, familial adenomatous polyposis (FAP), MUTYH associated 
polyposis (MAP) and the hamartomatous polyposis syndromes, like Peutz-Jeghers 
syndrome (PJS), juvenile polyposis syndrome (JPS), and Cowden syndrome (figure 3). 
Besides these syndromes, a new syndrome has been recently described, the polymerase 
proofreading-associated polyposis (PPAP), which is characterized by germline missense 
mutations in the POLE and POLD1 genes (Palles et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 - Circle  graph  illustrating  the  genotypic  and  phenotypic  heterogeneity  in  CRC. AC-1: 
Amsterdam Criteria 1; MMR: mismatch repair; FAP: familial adenomatous polyposis; AFAP: attenuated 
familial adenomatous polyposis; HBCC: hereditary breast and colorectal cancer; PJS: Peutz-Jeghers 
syndrome; FJP: familial juvenile polyposis; CD: Cowden’s disease; BRRS: Bannayan-Ruvalcaba-Riley 
syndrome (Lynch and Shaw, 2013). 
 
3. Anatomy and physiology of the large bowel   
 
The principal functions of the large bowel are absorption of water and electrolytes 
from the chyme to form solid feces, and storage of fecal matter until it can be expelled 
(Hall, 2010; Van De Graaff, 2001). 
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The large intestine averages 1.5m in length and 6.5cm in diameter. Its first portion, 
the cecum, forms a blind-ended pouch from which extends the appendix. The colon 
consists of three relatively straight segments: the ascending, the transverse, and the 
descending portions (figure 4). The ascending colon lies retroperitoneally and lacks a 
mesentery, it is continuous with the transverse colon at the hepatic (right) flexure of the 
colon near the right inferior margin of the liver. The transverse colon has its own 
mesentery, the transverse mesocolon, and becomes continuous with the descending 
colon at the splenic (left) flexure of the colon. The descending colon extends from the left 
colic flexure to the superior opening of the pelvis. The terminal portion of the descending 
colon is S-shaped, forming the sigmoid colon, which empties into a relatively straight 
segment of the large intestine, the rectum, which ends at the anus (Widmaier et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - Anatomy of the colon and rectum. The main anatomic regions of the large intestine are the 
ascending colon, transverse colon, descending colon, sigmoid colon, and rectum (adapted from Rhoades and 
Bell, 2009). 
 
4. Diagnosis and staging of CRC 
  
4.1. Screening and diagnosis 
 
Colorectal cancer may be diagnosed as the result of a screening program or when 
a patient presents symptoms. A wide range of symptoms and signs are common, such as 
rectal bleeding, blood in the stool, abdominal pain, changes in bowel habits, nausea, 
vomiting, distention, anemia, fatigue, and weight loss (Centelles, 2011; DeVita et al., 
2011; Labianca et al., 2013). However, symptoms usually appear with more advanced 
disease, therefore it is essential to establish an effective population screening that can 
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offer the best prospects for reduction in mortality rates (Labianca et al., 2013). The aim of 
screening is to prevent the development of advanced cancers through detection of 
localized cancers or premalignant adenomas, which can be treated with a clearly curative 
intention (Cunningham et al., 2010; Labianca et al., 2013). The CRC screening is effective 
due to the long period between the development of early mucosal abnormalities and the 
development of invasive carcinoma (DeVita et al., 2011). Thus far, there is a range of 
options for CRC screening, with current technology falling into two general categories: (1) 
stool tests, which include fecal occult blood test (FOBT), fecal immunochemical test, and 
fecal DNA testing; and (2) structural exams, which include flexible sigmoidoscopy, 
colonoscopy (CSPY), double-contrast barium enema, and computed tomographic 
colonography (Levin et al., 2008). The FOBT is the least sensitive screening method and 
should be offered every one to two years. The CSPY, the gold standard for CRC 
screening, is capable of direct visualization of the colonic mucosa, enables both detection 
and removal of adenomatous polyps and should be offered every five to ten years 
beginning at age 50, or with shorter intervals if there is family history or confirmed 
inherited predisposition of the disease (Centelles, 2011; Levin et al., 2008).  
For CRC diagnosis, CSPY remains, like in screening, the gold standard 
(Cunningham et al., 2010; Labianca et al., 2013). Besides that, the computed tomography 
(CT) of the abdomen is recommended as primary local staging tool to assess growth of 
the colon tumor into the surrounding structures (Schmoll et al., 2012). Clinical or 
biochemical suspicion of metastatic disease should always be confirmed by adequate 
radiological imaging, usually a CT or, alternatively, magnetic resonance imaging or 
ultrasonography (Cutsem et al., 2014). Fluorodeoxyglucose-positron emission 
tomography (FDG–PET) is not recommended at the time of initial diagnosis, as it does not 
modify the treatment approach in the vast majority of patients (Labianca et al., 2013). 
Nevertheless, FDG-PET scan can be useful to characterize the extent of metastatic 
disease (Cutsem et al., 2014). Before any treatment carcinoembryonic antigen (CEA) 
should be determined, because this marker is useful for follow-up of CRC patients. 
Although it has a low predictive value for diagnosis due to its relatively low sensitivity and 
specificity, the CEA level may have a prognostic value (Labianca et al., 2013). After 
diagnosis, it is crucial to stage the tumor according to its pathological characteristics 
(Centelles, 2011). 
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4.2. Histopathology and staging  
 
In 2000, the World Health Organization (WHO) proposed a histological 
classification for tumors, which divides them into two categories: the epithelial and the 
non-epithelial tumors. The epithelial group includes the adenomas, carcinomas and 
carcinoid tumors, while the non-epithelial group comprises the lipomas, leiomyomas, 
leiomyosarcomas, gastrointestinal stromal tumors (GISTs) and malignant lymphomas 
(Hamilton and Aaltonen, 2000).  
Adenocarcinoma is the most common tumor type (approximately 85%), of which 
mucinous and signet ring adenocarcinoma constitute approximately 10%, the other tumor 
types being rare (Lanza et al., 2011; Marzouk and Schofield, 2011; Treanor and Quirke, 
2007). Conventionally, adenocarcinoma is characterized by glandular formation, with 
variability in the size and configuration of the glandular structures, and the gland lumina 
often contain cellular debris (Hamilton and Aaltonen, 2000). Most adenocarcinomas are 
moderately differentiated and lack specific histological features (Treanor and Quirke, 
2007). 
Pathologic tumor staging remains the fundamental guide for prognostic and 
treatment decision. Accurate and consistent pathological staging of CRC is vital. A large 
number of staging systems have been developed for CRC over the years, but use of the  
Tumor, Node, Metastasis (TNM) staging system of the American Joint Committee on 
Cancer (AJCC) and of the International Union Against Cancer (UICC) is widely 
recommended (Centelles, 2012). In the TNM system, the designation “T” is the extent of 
invasion of the tumor through the bowel wall at the time of diagnosis. The designation “N” 
refers to the status of the regional lymph nodes, and “M” indicates the distant metastatic 
disease, including nonregional lymph nodes (Centelles, 2012; Compton, 2003; Fleming et 
al., 2012; Treanor and Quirke, 2007). These three letters are combined with numbers, 
from 0 to 4, in  order  to  designate  increasing  severity  and  progression  of  the  disease 
(table 1) (Centelles, 2012; Fleming et al., 2012). To assess the stage, the information of 
each letter should be combined. The stage is expressed in Roman numerals from stage I, 
the least advanced, to stage IV, the most advanced (table 2) (Centelles, 2012).  
Another factor used to analyze the survival is the grade of the cancer. Grade is a 
description of how closely the cancer looks like normal colorectal tissue when seen under 
a microscope. Adenocarcinomas are graded predominantly on the basis of the extent of 
glandular appearances, and should be divided into well (grade 1), moderately (grade 2) 
and poorly differentiated (grade 3), or into low-grade (encompassing well and moderately 
differentiated adenocarcinomas) and high-grade (including poorly differentiated 
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adenocarcinomas and undifferentiated carcinomas) (Centelles, 2012; Hamilton and 
Aaltonen, 2000). 
 
 
Table 1 - TNM classification of colorectal cancer (Hamilton and Aaltonen, 2000). 
 
TNM: Tumor, Node, Metastasis 
 
 
 
Table 2 - Staging groups for colorectal cancer, according to AJCC guidelines (Hamilton and Aaltonen, 2000). 
 
 
Stage 0 Tis N0 M0 
Stage I 
T1 N0 M0 
T2 N0 M0 
Stage II 
T3 N0 M0 
T4 N0 M0 
Stage III 
Any T N1 M0 
Any T N2 M0 
Stage IV Any T Any N M1 
 
AJCC: American Joint Committee on Cancer 
T Primary Tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ; intraepithelial or invasion of lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 
Tumor invades through muscularis propria into subserosa or into non-preitonealized 
pericolic or perirectal tissues 
T4 
Tumor directly invades other organs or structures and/or perforates visceral 
peritoneum 
N Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 3 regional lymph nodes 
N2 Metastasis in 4 or more regional lymph nodes 
M Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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5. Colorectal cancer treatment 
 
Less than a half of CRC patients are found in stage I and II, with the majority of 
cases diagnosed with advanced disease (Carethers, 2008). Approximately 20 to 25% of 
patients with the disease already present metastases at the time of diagnosis, and 50 to 
60% of the remainder will develop metastases (Segal and Saltz, 2009). Among  the  
different  approaches, surgery  remains  the most common treatment  of  CRC with 
curative intent (Labianca et al., 2013). Additionally, some proportion of patients will have 
residual micrometastases, which are the targets of additional adjuvant therapy. The 
standard treatment is 5-Fluorouracil (5-FU), in combination with leucovorin and oxaliplatin 
(FOLFOX) (Carethers, 2008; Labianca et al., 2013). For rectal cancer, radiotherapy and 5-
FU adjuvant or neoadjuvant based therapy are currently the most accepted options for 
stage II and III of the disease (Cutsem et al., 2014; Hirsch, 2011).  
For most patients with metastatic CRC (mCRC), treatment is palliative rather than 
curative. Chemotherapy regimens for stage IV colon cancer include FOLFOX, FOLFIRI 
(5-FU, leucovorin, and irinotecan) and CAPOX (capecitabine and oxaliplatin) (Carethers, 
2008; Labianca et al., 2013). Specific growth factor inhibitors, such as bevacizumab and 
cetuximab added to the 5-FU-based regimens improve tumor retraction and increase 
survival rates of the mCRC patients (Carethers, 2008). Bevacizumab is an antibody that 
inhibits blood-vessel formation by binding to vascular endothelial growth factor A (VEGF-
A) effecting cell signaling pathways that enhance angiogenesis, and thus the blood supply 
for tumors are reduced (Cutsem et al., 2014; Hagan et al., 2013). Cetuximab is an 
antibody that binds to the extracellular domain of the epidermal growth factor receptor 
(EGFR) and blocks ligand-induced receptor signaling (Cutsem et al., 2014). An alternative 
to cetuximab, having the same mode of action, is panitumumab (Schmoll et al., 2012). 
The effect of cetuximab and panitumumab has been limited to patients harboring Kirsten 
rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma RAS viral oncogene 
homolog (NRAS) wild-type tumors (Douillard et al., 2013; Stintzing et al., 2012).  
 
6. Colorectal carcinogenesis 
 
A genetic model of CRC, the adenoma-carcinoma sequence model, proposed 
approximately two decades ago by Fearon and Vogelstein, explains the stepwise 
formation of sporadic CRC from normal colonic tissues (Fearon, 2011). This model states 
that (1) CRC is the result of mutational activation of oncogenes and/or mutational 
inactivation of tumor suppressor genes; (2) formation of malignant tumor requires the 
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occurrence of mutations in at least four to five genes, whilst for benign tumorigenesis 
fewer changes are sufficient; (3) the total accumulation of mutations rather than their order 
of appearance is of relevance, to define the tumor’s biologic behavior; and (4) in some 
cases, mutant suppressor genes, even in the heterozygous state, appear to exert a 
phenotypic effect (Fearon and Vogelstein, 1990). However, there are several lines of 
evidence which suggest that not all adenomas will progress to carcinomas. Probably this 
progression occurs over years to decades; for instance, adenomas roughly 1cm in size 
may have an approximately 10 to 15% chance of progressing to carcinoma over a 10-year 
period (IJspeert et al., 2015; Fearon, 2011).  
The earliest identifiable lesion in CRC formation is the aberrant crypt focus, small 
areas of epithelium with irregular glandular architecture, which have been reported to 
harbor mutations in adenomatous polyposis coli (APC), KRAS and tumor protein p53 
(TP53) genes. However, the relationship between aberrant crypt foci and adenomas is still 
inconclusive (Fearnhead et al., 2002).  
The adenoma carcinoma model gradually progressed to a more complex model, 
the chromosomal instability (CIN) pathway. Additionally, at least two more molecular 
pathways have been described, the microsatellite instability (MSI) and the CpG island 
methylator phenotype (CIMP) pathways (Legolvan et al., 2012). On the other hand, the 
definitions of the three pathways are not mutually exclusive and it is believed that a tumor 
can occasionally show features of multiple pathways, although the extent and nature of 
this overlap remains to be determined (Migliore et al., 2011).  
 
6.1. Chromosomal instability pathway  
 
Chromosomal instability is the most common type of genomic instability accounting 
for 70 to 85% of sporadic CRC. These tumors are characterized by mutations in APC, 
TP53, and KRAS and by frequent allelic loss of 18q. Aneuploidy, amplifications, 
translocations and a high frequency of loss of heterozygosity (LOH) are also common in 
these tumors (Brogaert and Prenen, 2014; Kheirelseid et al., 2013).  
Mutation and/or loss of the APC gene, located on chromosome 5q21, is usually the 
earliest genetic event, and it is involved in a wide variety of cellular processes, including 
migration, adhesion, proliferation, differentiation, apoptosis, and chromosomal segregation 
(Fearnhead et al., 2002; Fearon, 2011; Leslie et al., 2002). APC is a multifunctional 
protein with several domains that is known to interact with several proteins, including β-
catenin, γ-catenin, glycogen synthase kinase (GSK)-3β, axin, tubulin, and end binding 1 
(Kheirelseid et al., 2013). Although the APC protein has multiple critical cellular functions, 
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the best-established role for APC in the cancer process is the ability to regulate 
intracellular β-catenin protein levels. This pathway is called the canonical or β-catenin-
dependent wingless-type MMTV integration site family (Wnt) signaling pathway (Fearon, 
2011). In the presence of normal APC protein or in the absence of external signals, β-
catenin is co-localized with E-cadherin, a protein involved in cell-cell adhesion. 
Subsequently, APC binds and collaborates with the protein Axin to promote sequential 
phosphorylation of β-catenin, by GSK3β, leading to the proteasomal degradation of β-
catenin (Fearon, 2011; Krause and DuBois, 2001). In the absence of functional APC, Wnt 
signaling is inappropriately and constitutively activated. Consequently, GSK3β is 
inactivated and β-catenin remains unphosphorylated. As a result, β-catenin accumulates 
in the cytoplasm and translocates to the nucleus, where it functions as a transcriptional 
coactivator. The genes regulated by the β-catenin can play important roles in neoplastic 
transformation. This pathway is essential to colorectal tumorigenesis, and more than 90% 
of patients present alterations that affect it (Walther et al., 2009).  
Activation of the KRAS oncogene represents an important step in the evolution 
towards CRC. KRAS mutations are found in at least 37 to 40% of sporadic colorectal 
adenomas larger than 1cm and in carcinomas, but are infrequent in adenomas smaller 
than 1cm in size, indicating a role in adenoma progression rather than initiation 
(Kheirelseid et al., 2013). KRAS is a proto-oncogene, located at 12p12.1, member of the 
rat sarcoma viral (RAS) family genes, which includes KRAS, NRAS, and Harvey rat 
sarcoma viral oncogene homolog (HRAS), which encodes highly conserved proteins 
involved in signal transduction (Morán et al., 2010). KRAS is a guanosine 5’-triphosphate 
(GTP) binding protein with intrinsic GTPase activity. When it is bound to GTP, the RAS 
protein is active, but becomes inactive when GTP is hydrolyzed to guanosine 5’-
diphosphate (GDP). RAS proteins are central mediators downstream of growth factor 
receptor signaling pathways and therefore are critical for cell proliferation, survival, and 
differentiation (Leslie et al., 2002; Morán et al., 2010; Walther et al., 2009). KRAS and 
NRAS mutation status has been established as a negative predictive factors for treatment 
with EGFR inhibitors (Douillard et al., 2013; Walther et al., 2009). The RAS proteins exert 
effects on several downstream signaling cascades, including the Mitogen-activated 
protein kinase (MAPK) pathway, which is involved in cell proliferation, and the 
Phosphatidylinositol 3-kinase (PI3K) pathway, which is involved in cell survival (Kanthan 
et al., 2012).  
Allelic loss of the long arm of chromosome 18 has been reported in approximately 
70% of sporadic CRC. This region contains many candidate tumor suppressor genes, 
including the DCC netrin 1 receptor (DCC), SMAD family member 2 (SMAD2) and SMAD 
family member 4 (SMAD4). DCC encodes netrin-dependent transmembrane receptor that 
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supports the regulation of apoptosis and may play a role in cell motility. DCC mutations 
are only found in 10 to 15% of sporadic colorectal carcinomas and occur late in the 
tumorigenesis (Hughes and Huang, 2011). SMAD2 and SMAD4 genes encode proteins 
that function downstream of the Transforming growth factor, beta 1 (TGFB1) receptor 
complex. Mutations that inactivate SMAD4 are found in approximately 10 to 15% of 
CRCs, and SMAD2 mutations are found in approximately 5% of CRCs (Walther et al., 
2009).  
The TP53 gene, located on 17p13.1, encodes the TP53 protein, which has 
abnormal expression in more than 50% of human tumors. TP53 produces a protein that 
normally induces G1 cell cycle arrest to allow for DNA repair. Conversely, if there is an 
excess amount of DNA damage, it will induce apoptosis (Hughes and Huang, 2011). 
Mutation or loss of TP53 usually occurs at the time of the transition from adenoma to 
carcinoma. The frequency of TP53 abnormalities increases with tumor progression. Thus, 
alterations are found in 4 to 26% of adenomas, 50% of adenomas with invasive foci, and 
in 50 to 75% of CRCs (Morán et al., 2010) (figure 5). 
 
 
Microsatellite instability pathway  
 
Microsatellite instability occurs in approximately 15 to 20% of sporadic CRC. 
Tumors with MSI presents a near diploid karyotype and are characterized by 
accumulation of mutations in coding and noncoding microsatellite sequences (Brogaert 
and Prenen, 2014; Migliore et al., 2011; Morán et al., 2010). Microsatellites are short 
tandem repeats distributed throughout the genome highly variable and prone to mutation, 
due to slipped strand mispairing (slippage) during DNA replication. Mutations in 
microsatellites are usually repaired by mismatch repair (MMR) enzymes, but when these 
repair enzymes are inactivated by hypermethylation of the promotor or mutation of the 
Figure 5 - Chromosomal instability (CIN) pathway: This pathway is thought to be driven by mutational events 
in individual genes. Some of these mutations such as inactivating mutations of tumor suppressor genes, like 
the APC, and activating mutations of proto-oncogenes, like KRAS, give the cell a growth advantage. 
Subsequent mutations of other genes like SMAD4 and TP53 and clonal expansion of cells with additional 
growth advantages ultimately leads to cancer (Adapted from Mundade et al., 2014). 
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MMR genes, mutations accumulate as DNA is replicated, leading to MSI (Beggs and 
Hodgson, 2008). There are at least six genes in the MMR system: mutL homolog 1 
(MLH1), mutS homolog 2 (MSH2), mutS homolog 3 (MSH3), mutS homolog 6 (MSH6), 
PMS1 homolog 1, mismatch repair system component (PMS1), and PMS1 homolog 2, 
mismatch repair system component (PMS2).  
Through the MSI pathway, CRC progression is accelerated by a rapid mutation 
accumulation in coding repetitive sequences of target genes with key cellular roles, such 
as genes related with DNA repair, apoptosis, signal transduction, and cell cycle. For 
instance, mutation in the transforming growth factor beta receptor II (TGFBR2) inactivates 
gene function and has been observed in about 90% of CRC with MSI (Biswas et al., 
2008). A panel of five microsatellite markers (D2S123, D5S346, D17S250, BAT25, and 
BAT26) was proposed for defining the MSI tumor status. If the tumors have instability in 
≥30% of these markers, they are defined as microsatellite instability-high (MSI-H) tumors, 
whereas microsatellite instability-low (MSI-L) tumors are defined as having instability in 
<30% of these markers, and those that show 0% of instability at those five loci are termed 
microsatellite stable (MSS) (Boland et al., 1998).   
These tumors display unique clinicopathological features. The majority of sporadic 
MSI CRC are located in the right colon, presents local lymphocyte infiltration, tend to be 
poorly differentiated, of mucinous histology type, and the patients show a better overall 
survival when comparing with patients diagnosed with MSS tumors (Kim et al., 2013; 
Migliore et al., 2011; Morán et al., 2010) (figure 6). 
 
6.2. CpG island methylation pathway  
 
A third pathway through which CRC progresses, found in 15 to 20% of the cases, 
is the CpG island methylator phenotype (CIMP). This pathway is characterized by a vast 
hypermethylation of promotor CpG island sites, resulting in the inactivation of several 
suppressor genes (Al-Sohaily et al., 2012; Brogaert and Prenen, 2014; Kanthan et al., 
2012). CpG islands are regions of DNA where there is a large number of contiguous 
Figure 6 - Microsatellite instability (MSI) pathway: is characterized by inactivation of the mismatch repair 
(MMR) genes. The resultant failure of MMR leads to mutations in many genes, such as growth factor receptors 
like TGFBR2, among others (Adapted from Mundade et al., 2014). 
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cytosine (C) and guanine (G) base pairs linked by a phosphodiester bond (Beggs and 
Hodgson, 2008). Several CpG dinucleotides, which are methylated in normal cells, are 
unmethylated in cancer. In cancer cells, these islands may also be aberrantly 
hypermethylated, causing inappropriate silencing of gene expression. DNA methylation is 
an enzymatic process that adds a methyl group to the 5-position of cytosine by DNA 
methyltransferases to produce 5-methylcytosine. Methylation of CpG islands within the 
promoter region cause transcriptional silencing, whereas methylation in CpG sites outside 
the promoter site may cause transcriptional activation (Beggs and Hodgson, 2008; 
Kanthan et al., 2012). Several genes involved in colorectal carcinogenesis are found to be 
silenced by DNA hypermethylation, including APC, MLH1, and O-6-methylguanine-DNA 
methyltransferase (MGMT). Five genes have been selected to serve as markers for CIMP: 
CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1. CIMP positivity is defined by 
methylation of at least three markers (Weisenberger et al., 2006). The CIMP positive 
tumors can be also divided into CIMP-high (CIMP-H) and CIMP-low (CIMP-L). The CIMP-
H CRCs are often characterized by the presence of the MLH1 promoter hypermethylation 
and the most common B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation, 
the p.Val600Glu, also known as V600E. The CIMP-L CRC is often related to KRAS 
mutations (Fearon, 2011; Walther et al., 2009). 
The CIMP colorectal tumors have distinct characteristics, are more common in 
females, older and smoking patients and the tumors are proximally located in the colon. 
Pathologically, CIMP tumors are often poorly differentiated, of mucinous or signet ring 
histology (Al-Sohaily et al., 2012; Curtin et al., 2011) (figure 7). 
 
7. Polymerase epsilon (POLE) 
 
Despite all the knowledge about the molecular pathways in sporadic CRC, the 
picture of somatic genetic changes in colorectal tumorigenesis is far from complete. To 
complete the gaps, The Cancer Genome Atlas (TCGA) exome sequencing project 
published the result of full genomic profiling of 224 colorectal cancer samples (Cancer 
Figure 7 - CpG island methylation (CIMP) pathway: This pathway is thought to be driven by hypermethylation 
of several genes and presents BRAF mutation (Adapted from Mundade et al., 2014). 
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Genome Atlas Network, 2012). This work confirmed many previous mutational findings in 
CRC. Additionally, this study identified new rare findings, such as polymerase, epsilon, 
catalytic subunit (POLE) mutations in a small subset of MSS CRC that are nevertheless 
hypermutated. These findings suggest that CRC associated with POLE mutations may 
represent a distinct CRC subtype.  
The POLE gene (LRG_789; NM_006231.3) is located in 12q24.33 and encodes 
the proofreading (exonuclease) subunit of polymerase epsilon (POLE) with 2286 amino 
acids. The exonuclease domain of POLE, which corresponds to residues 268-471, is 
divided in five amino acids conserved motifs designated Exo I, II, III, IV and V. These Exo 
motifs have different and important contributions to exonuclease activity (Henninger and 
Pursell, 2014; Pursell and Kunkel, 2008).  
There are at least fifteen eukaryotic DNA polymerases identified so far, which are 
involved in gene replication and DNA repair. Eukaryotic DNA polymerases, based on 
sequence homology and structural similarities, can be subdived into five families, 
designated A, B, X, Y, and RT (table 3) (Hübscher et al., 2002). The B family includes the 
main replicative enzymes in eukaryotes. Most family B polymerases contain an associated 
3’-5’ exonuclease domain and are multisubunit (Garcia-Diaz and Bebenek, 2008). The 
POLE (often called as Polε) is a member of the B family of DNA polymerases and it is 
composed of four subunits, a large catalytic subunit of aproximately 260 kDa and three 
associated subunits of 55, 17 and 12 kDa. The catalytic subunit of POLE is highly 
conserved among eukaryotic species and contains both the DNA polymerase and the 3’-5’ 
exonuclease activities in its N-terminal half, while the C-terminal domain, with a conserved 
“zinc finger” motif, is catalytically inactive and appears to play a structural role in the 
enzyme. The accessory subunits in POLE do not appear to contain any catalytic activities 
and do not appear to influence the catalytic rates of the polymerase or exonuclease active 
sites of the N-terminal portion of the catalytic subunit. They do, however, play important 
roles in the biological pathways in which POLE is found (Agbor et al., 2013; Henninger 
and Pursell, 2014; Hogg and Johansson, 2012; Purssel and Kunkel, 2008; Pospiech and 
Syväoja, 2003; Preston et al., 2010; Reha-Krantz, 2010).  
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Table 3 - Summary of eukaryotic DNA polymerase functions. 
 
Family DNA polymerases* (#) Function 
A 
POLG (Polγ) Mitochondrial DNA replication and repair 
POLQ (Polθ) DNA repair 
POLN (Polν) DNA repair and homologous recombination 
B 
POLE (Polε) DNA replication and repair 
POLA (Polα) DNA replication initiation 
POLD (Polδ) DNA replication and repair 
POLZ (Polς) Translesion synthesis 
X 
POLB (Polβ) BER and meiotic recombination 
POLL (Polλ) BER 
POLM (Polµ) NHEJ 
Y 
POLH (Polη) Translesion synthesis 
POLI (PolƖ) Translesion synthesis 
POLK (Polκ) Translesion synthesis 
REV1 
Translesion synthesis and anchor of several DNA 
polymerases 
RT Telomerase Telomere maintenance 
 
*Human Genome Organization (HUGO) nomenclature; #Common synonym name; BER: Base excision repair; 
NHEJ: Nonhomologous end joining. 
 
7.1. The role of POLE 
 
Genomic DNA is normally replicated with remarkable accuracy that is achieved 
through a network of conserved pathways that repair DNA damage and correct DNA 
polymerase errors. The primary guardians of DNA replication fidelity are polymerase 
proofreading and the postreplication MMR system (Albertson et al., 2009; Lange et al., 
2011). Maintenance of the low mutation rate relies mostly on three DNA replication fidelity 
mechanisms: (1) accurate nucleotide selection by replicative DNA polymerases POLA, 
POLD and POLE; (2) proofreading of errors by the 3’-exonuclease activity of POLD and 
POLE; (3) correction of mispairs by the MMR system. These processes act in series 
keeping the mutation rate per cell division at a low level (less than 10-10) (Kane and 
Shcherbakova, 2014). The POLA initiates DNA synthesis on both leading and lagging 
strands by providing an RNA primer and synthesizing approximately 20-30 bases of DNA 
(Lange et al., 2011). POLE and POLD are responsible for the bulk of chromosomal DNA 
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synthesis during cell division. POLE and POLD are the principal leading- and lagging-
strand DNA polymerases, respectively (Albertson et al., 2009). POLE and POLD possess 
an intrinsic 3′-5′ proofreading domain, the exonuclease domain, which removes incorrectly 
inserted nucleotides during DNA synthesis (figure 8). The base substitution error rates of 
POLD and POLE are approximately 10–5, the lowest of all the described DNA 
polymerases (Lange et al., 2011; Palles et al., 2013). The role of POLE, however, is not 
limited to DNA replication, since it has been implicated in several pathways, such as 
epigenetic silencing, cell cycle regulation, sister chromatid adhesion and possibly DNA 
recombination during the repair of DNA lesions (Pursell and Kunkel, 2008). 
 
 
 
Figure 8 - Schematic of a DNA replication fork with POLE and POLD on the leading- and lagging- strands, 
respectively. Major determinants of accurate DNA synthesis are highlighted in yellow. The polymerase 
domains of POLD and POLE distinguish between correct and incorrect dNTPs (deoxynucleotides). If an error 
occurs, these are corrected primarily by the intrinsic proofreading exonuclease (EXO) present in each 
polymerase. Errors that escape proofreading are rectified by mismatch repair (MMR) (Preston et al., 2010). 
 
7.2. Germline mutations in POLE predispose to a multi-tumor 
phenotype 
 
In 2013, Palles and collaborators reported that heterozygous germline variants in 
the proofreading domain of the DNA polymerases, namely, the POLE p.(Leu424Val) 
variant and the POLD1 p.(Ser478Asn) variant, predispose to CRC. Both mutations are 
associated with dominant inheritance of the disease and confer high-penetrance 
predisposition to multiple colorectal adenomas, early-onset CRC, multiple CRCs, and 
endometrial cancer (EC). They called the disease polymerase proofreading-associated 
polyposis (PPAP) (Palles et al., 2013). The phenotype varies among carriers, some 
individuals have a predominantly multiple-adenoma phenotype, similar to MAP, while 
other individuals present large adenomas or early-onset carcinoma, thus resembling 
Lynch syndrome. There is currently no evidence that mutation carriers are at risk of upper-
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gastrointestinal tumors, but female carriers of the POLD1 p.(Ser478Asn) variant have an 
increased risk of EC. The PPAP phenotype overlaps with those associated with germline 
mutations in APC, MUTYH, and MMR genes (Briggs and Tomlinson, 2013). Tumors of 
POLE and POLD1 mutation carriers are MSS and harbor mutations in KRAS, BRAF, 
APC, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) 
and F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase (FBXW7), all 
genes with established roles in pathogenicity of CRC, suggesting that the tumors at least 
partly follow the classical pathway of colorectal tumorigenesis (Briggs and Tomlinson, 
2013; Palles et al., 2013). 
Elsayed and co-workers, in 2014, also identified three families with the previous 
identified POLE p.(Leu424Val) variant. These patients developed multiple colorectal 
adenomas and two showed early onset MSI CRC, which is in contrast with the previously 
identified POLE and POLD1 germline variant carriers who developed MSS tumors 
(Elsayed et al., 2014; Palles et al., 2013).  
Rohlin and colleagues, in 2014, also reported another POLE variant, the 
p.(Asn363Lys). This alteration seems to have a profound effect on the substrate binding at 
the active site of the proofreading exonuclease domain. Family members carrying this 
mutation reveal a highly penetrant predisposition not only to CRC, but also to extra-
intestinal tumors, such as ovarian, endometrial and brain tumors (Rohlin et al., 2014). 
In summary, there is at least one germline mutation hotspot in POLD1, the 
p.(Ser478Asn), and two in POLE, the p.(Leu424Val) and the p.(Asn363Lys) (these two 
are depicted in figure 9). 
 
Figure 9 - The structure of POLE demonstrating the position of germline and somatic hotspot mutations of 
POLE. Conserved exo motifs I–V within the exonuclease domain are highlighted in blue. The polymerase 
domain and zinc finger are represented in yellow and orange, respectively.   
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7.3. POLE somatic mutations in sporadic CRCs 
 
The TCGA consortium, using exome sequencing approaches, identified recurrent 
somatic missense mutations in POLE. It was found that almost all of the hypermutant, 
MSS cancers had exonuclease domain mutations (EDMs) in POLE. Seven POLE 
exonuclease domain mutations in the TCGA cohort, out of a total of 224 CRCs (3%), were 
missense changes, although the mutation p.(Leu424Val) previously found in the germline 
was absent (Briggs and Tomlinson, 2013; Cancer Genome Atlas Network, 2012). Three 
recurrent changes were found, the p.Pro286Arg, the p.Val411Leu, and the p.Ser459Phe. 
Recently, unpublished data from the TCGA have confirmed codons 286, 411, and 459 as 
somatic mutation hotspots (figure 6) (Briggs and Tomlinson, 2013; Heitzer and Tomlinson, 
2014). Additionally, they found POLE EDMs in about 7% of sporadic EC, including some 
previously detected in CRCs (Cancer Genome Atlas Network, 2013). Similar to CRC, 
POLE mutations in ECs were associated with an ultramutator, but MSS phenotype, 
characterized by an excess of substitution mutations (Heitzer and Tomlinson, 2014). All of 
these alterations are predicted to have a direct effect on DNA binding and/or activity 
(Palles et al., 2013). 
In addition to colorectal and endometrial cancers, POLE mutations were observed 
in <1% of glioblastoma multiforme, low grade glioma, lung adenocarcinoma, pancreatic 
ductal adenocarcinoma, breast invasive carcinoma, bladder adenocarcinoma, renal cell 
chromophobe carcinoma, head and neck cancer, and stomach cancers (Shinbrot et al., 
2014).  
Interestingly, although POLD1 is highly homologous to POLE and germline 
mutations have been described in both genes, to our knowledge there is no good 
evidence of pathogenic somatic mutations in POLD1 exonuclease domain (Briggs and 
Tomlinson, 2013).  
 
7.4. Role of POLE in tumorigenesis 
 
Structural data strongly suggest that the POLE exonuclease mutations impair 
polymerase proofreading. Studies in yeast have shown that mutations in the proofreading 
domains of POL2 or POL3 (homologous of POLE and POLD1, respectively, in humans) 
increase spontaneous mutation rates (Morrison et al. 1991; Simon et al., 1991). Mapping 
mutations onto a hybrid structure of yeast DNA polymerase (3iay) and T4 polymerase 
indicates that they mostly lie along the DNA-binding pocket of the exonuclease domain. 
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The residue Leu424 of POL2 packs at the interface between two helices that form the 
base of the exonuclease active site. Mutations in this residue are predicted to distort the 
packing of the helices, and all the active site, affecting nuclease activity. The residue 
equivalent to POL2 mutation at amino acid 286 is a conserved Exo I residue localized in 
the DNA binding pocket adjacent to the exonuclease active site, with its side chain very 
close to the nascent single-stranded DNA. Substitutions at this site probably perturbe the 
structure of the DNA binding pocket. The substitution of serine by phenylalanine in codon 
459, which maps to the Exo III motif, leads to a reduction on proofreading activity. Codon 
411 of POL2 maps to a conserved residue between the Exo II and Exo III motifs, although 
is not predicted to interact with DNA or catalytic site residues, suggesting that the 
mechanisms on tumorigenesis may be through secondary effects on the binding pocket 
(Briggs and Tomlinson, 2013; Heitzer and Tomlinson, 2014; Henninger and Pursell 2014; 
Palles et al., 2013; Shinbrot et al., 2014). 
Furthermore, Albertson and collaborators (2009) showed that loss of Pole 
proofreading confers a strong mutator phenotype and high incidence of spontaneous 
neoplasms in mice. The homozygous PoleExo-/Exo- die prematurely of intestinal adenomas 
and adenocarcinomas, demonstrating that proofreading functions are required to 
suppress tumorigenesis. Heterozygous PoleWT/Exo- mice had tumor incidence and mortality 
indistinguishable from the parental mice (Albertson et al., 2009).   
 Hypermutation is thus a very plausible consequence of exonuclease mutations in 
POLE. However, it remains unclear if this is the only tumor-promoting consequence of 
these mutations. It will also be intriguing to determine whether proofreading deficiency has 
any effect on polymerase processivity, since negative effects on this function may be 
selectively deleterious for the cell (Briggs and Tomlinson, 2013; Heitzer and Tomlinson, 
2014; Palles et al., 2013).  
 
 
 
The functional consequences and clinical relevance of polymerase mutations are 
not yet clear. The immediate priority is to determine the full POLE mutation spectra. The 
identification of somatic POLE mutations that cause CRC is only the first step to better 
understand their role in colorectal carcinogenesis. This knowledge may contribute to the 
development of new forms of early detection and/or treatment. Finally, the discovery of a 
new type of CRC based on POLE mutations beyond the previous established subtypes 
(CIN, MSI and CIMP) raises the prospect of a possible future reclassification of the CRC 
pathways (Briggs and Tomlinson, 2013; Heitzer and Tomlinson, 2014).  
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II. Aims of the study  
 
Recently, germline and somatic mutations in the POLE gene have been described. 
However, the role of POLE mutations in advanced CRCs has not yet been evaluated.  
 
Therefore, the specific goals of this thesis were: 
 To perform mutation screening in the entire exonuclease domain of the 
POLE gene in a series of metastatic CRCs;  
 
 To evaluate the somatic or germline nature of the detected POLE 
mutations; 
 
 To characterize the clinicopathological and genetic features of CRCs 
harboring mutations in the POLE gene. 
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III. Material and methods 
 
1. Clinical samples 
  
A consecutive series of formalin-fixed paraffin embedded colorectal 
adenocarcinoma samples from 400 patients were retrospectively analyzed. All these 
samples belong to patients referred to the Genetics Department of IPO-Porto between 
August 2008 and December 2012 for KRAS mutation analysis. Of these 400 samples, 93 
were excluded due to lack/poor quality DNA. 
Median age of diagnosis was 59 years and tumor localization was as follows: 50 
ascending colon, 32 descending colon, four transverse colon, 84 sigmoid colon and 131 
rectum tumors. Histopathology reports were not available for six cases. 
 
2. DNA extraction and quantification 
 
Tumor areas containing at least 50% of tumor cells were delimited, by a 
pathologist, in the hematoxylin and eosin (H&E) stained slides of each sample. The 
corresponding unstained slides were immersed in xylene [Sigma-Aldrich, Steinheim, Germany] and 
twice in ethanol 100% [Merck, Darmstadt, Germany] for 5 minutes each to remove the paraffin. 
Tumor areas, which were previously delimited by comparison with the correspondent H&E 
stained slides, were macrodissected and transferred to a centrifuge tube and 40 µL of 
proteinase K [Gibco Invitrogen, Carlsbad, CA, USA] (10 mg/mL) were added, followed by incubation at 
55°C overnight. DNA was isolated using the QIAamp® DNA FFPE Tissue Kit [Qiagen, Hilden, 
Germany], following the manufacturer’s instructions. Finally, the DNA was quantified by 
spectrophotometry with NanoDrop ND-1000® [NanoDrop Technologies, Wilmington, DE, USA]. In samples 
with mutations, the normal mucosa was also extracted from the same slide of tumor, to 
confirm the somatic status of mutations, using the same approach. 
 
3. DNA sequencing 
 
Somatic mutation screening in the exonuclease domain of POLE (exon 9-14) was 
performed by Sanger sequencing (Sanger et al., 1977). For this purpose, approximately 
20 ng of DNA were amplified in a solution containing 1x Taq reaction buffer [Thermo Fisher 
Scientific, Rockford, USA] (75 mM Tris-HCl, 20 mM (NH4)2SO4), 1.25 mM of MgCl2 [Thermo Fisher 
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Scientific], 0.5 mM dNTP mix [Thermo Fisher Scientific], 0.17 mM of each primer (reverse and forward) 
[frilabo, Portugal], 1 U of Taq DNA polymerase [Thermo Fisher Scientific], in a final reaction volume of 30 
µL. Primer sequences were kindly provided by Professor Ian Tomlinson (Wellcome Trust 
Centre for Human Genetics, University of Oxford, UK). PCR reaction was performed in a 
termocycler [Gene Amp PCR Systern 9700, Perkin-EImer, Waltham, Massachusetts, USA] according to the following 
conditions: an initial denaturation step at 95°C for 10 min, followed by 35 cycles of 95°C 
for 45 seconds, annealing step at 58°C for 45 seconds and a 45 seconds extension step 
at 72°C. A final extension step was done at 72°C for 10 min. Amplified PCR products were 
then analyzed by electrophoresis in a 2% (w/v) agarose gel [Gibco Invitrogen] stained with green 
safe [Sigma-Aldrich] 0.05 µL/mL.  
Subsequently, the PCR products were purified using the ExoSAP-IT method for 
the removal of primers and dNTPs in excess. Samples were purified adding 2 µL of 
ExoSAP solution (Exonuclease I [Thermo Fisher Scientific] (20 U/μL) and Fast Thermosensitive 
Alkaline Phosphatase [Thermo Fisher Scientific] (1 U/μL), in a proportion of 1:2) to 5 µL of the PCR 
product, followed by incubation at 37ºC for 50 minutes, and enzyme inactivation at 80ºC 
for 15 minutes.  
The purification was followed by the sequencing reaction in which the BigDye® 
Terminator v1.1 or v3.1 Cycle Sequencing Kit [Applied Biosystems, Foster City, CA, USA] was used. The 
reaction consisted on mixing 3.4 μL of sequencing buffer, 0.5 µL of Big Dye® Terminator 
v1.1 or v3.1, containing dNTPs, ddNTPs-fluorocromes, MgCl2 and Tris-HCl buffer, 0.32 µL 
of one of the primers (forward or reverse), and bidestilled sterile water [B. Braun, Foster City, CA, 
USA] and 1 µL of the previously purified DNA to reach a final reaction volume of 10 µL. The 
sequencing reaction was performed and was consisted of an initial denaturation step at 
95ºC for 4 minutes, followed by 35 cycles of denaturation at 96ºC for 10 seconds, 
annealing at 50ºC for 10 seconds and extension at 60ºC for 2 minutes, with a final 
extension of 60ºC for 10 minutes. In order to remove excess of dNTPs, labeled ddNTPs 
and non-incorporated primer, the sequencing products were purified with IIlustra 
Sephadex® G-50 fine [GE Healthcare, Life Sciences, Cleveland, USA], according to standard procedures. 
After purification, 12 μL of Hi-DiTM Formamide [Applied Biosystems] were added to the sequencing 
products to help stabilize the single stranded DNA. The products were then analyzed in 
either an ABI PRISMTM 310 Genetic Analyzer [Applied Biosystems] or a 3500 Genetic Analyzer 
[Applied Biosystems] by capillary electrophoresis. The electropherograms of each sample were 
analyzed with the Sequencing Analysis Software v5.4 [Applied Biosystems]. All of them were 
analyzed at least twice, reviewed manually and with the Mutation Surveyor® DNA Variant 
Analysis Software v4.0.8 [Softgenetics, State College, PA, USA]. A second PCR amplification and DNA 
extraction was performed in all positive samples, followed by DNA sanger sequencing of 
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both strands. All POLE variants described are according to the LRG_789 (NM_006231.3) 
and to the Human Genome Variations Society guidelines.  
 
4. Microsatellite instability analysis 
 
Microsatellite instability was performed in the tumors with POLE mutations, using 
the set of five mononucleotide microsatellite markers (BAT26, BAT25, NR21, NR22 and 
NR24) recommended by the National Cancer Institute as an alternative to the Bethesda 
panel (Suraweera et al., 2002). The amplification reaction occurred in a total volume of 20 
µL of a solution containing: 1x Taq reaction buffer [Thermo Fisher Scientific] (75 mM Tris-HCl, 20 
mM (NH4)2SO4), 2.5mM MgCl2  [Thermo Fisher Scientific] 0.5mM dNTP's  [Thermo Fisher Scientific] (250 
µM dTTP, 250 µM dATP, 250 µM dGTP, 250 µM dCTP),  0.15 mM of primer [Frilabo], 0.6 U 
Taq DNA polymerase [Thermo Fisher Scientific] and 30 to 50 ng of DNA. PCR reaction was 
performed according to the following conditions: an initial denaturation step at 95°C for 10 
min, followed by 35 cycles of 95°C for 1 minute, annealing step at 55°C for 1 minute and a 
1 minute extension step at 72°C. A final extension step was done at 72°C for 10 min.  
Fragments were analyzed for length variations on an ABI PRISMTM 310 Genetic 
Analyzer [Applied Biosystems]. For this propose, about 0.1 µL of the reaction product was added 
to 15 µL of Hi-DiTM Formamide [Applied Biosystems], and to 0.4 µL of Gene Scan ROX (Carboxy-
X-Rhodamine) size standard [Applied Biosystems]. Allele sizes were determined using the Gene 
Mapper® software version 3.7 [Applied Biosystems]. The results were independently scored by 
two observers and an additional round of analyses confirmed the results. Tumors were 
characterized as MSI-H if they manifested instability at >30% of loci, MSI-L if unstable at 
<30% of loci, and MSS if they showed no instability at any loci. 
 
5. BRAF p.Val600Glu mutation analysis  
 
The BRAF c.1799T>A, p.Val600Glu, mutation was screened in all tumors with 
POLE mutations by PCR amplification and High Resolution Melting (HRM) analysis on a 
LightCycler-480 II Real-Time System [Roche Applied Science]. The PCR reaction mixture added to 
each well, of a 96 well plate, was composed of a pair of primers (forward and reverse), 
DNA of each sample and PCR reagents (table 4). To prevent contamination and/or 
evaporation, 15 μL of mineral oil were added to each well. The plate was then sealed with 
sealing film and centrifuged at 1500g for 2 minutes. 
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Table 4 - Components of the PCR reaction mixture for BRAF p.Val600Glu mutation analysis. 
 
PCR reaction mixture componentes 
2.5x LightScanner® Master Mix [Idaho] 4.0μL 
a)
Forward primer [Frilabo] 350nM 
a)
Reverse primer [Frilabo] 350nM 
DNA 20-100ng 
Reagent grade water [Idaho] 4.9μL 
Total reaction volume 10μL 
 
a) 
Primer sequences according to Mancini et al., 2010 
 
Amplification and melting curves were obtained and analyzed using the 
LightCycler® 480 Gene Scanning software v1.5 [Roche Applied Science]. 
As confirmation of this technique, single-nucleotide primer extension (SNuPE) was 
performed. After standard ExoSAP-IT purification, the SNuPE reaction and capillary 
electrophoresis was performed following the SNaPshot Kit [Applied Biosystems] manufacturer´s 
protocol. 
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IV. Results 
 
1. POLE mutational analysis  
 
We searched for mutations in the exonuclease domain of the POLE gene (exons 9 
to 14) in DNA tumor samples from 307 mCRC. Three heterozygous mutations were found 
in two cases (T286 and T368), which corresponds to a frequency of somatic POLE 
mutations of 0.65%. The mutations are at positions 857 and 901 in exon 9, and at position 
1376 in exon 14. The first mutation consists of a nonsynonymous substitution of a 
cytosine for a guanine (transversion, c.857C>G) in the second position of codon 286 (CCT 
 CGT), resulting in a nonconservative substituition of a Proline for an Arginine, 
p.Pro286Arg (figure 10). This mutation has been described as a mutation hotspot by 
Briggs and Tomlinson (2013) and in the COSMIC (Catalogue of somatic mutations in 
cancer) database. The second mutation consists of a nonsynonymous substitution of a 
guanine for an adenine (transition, c.901G>A) in the first position of codon 301 (GAT  
AAT), resulting in a nonconservative substituition of an Aspartic acid for an Asparagine, 
p.Asp301Asn (figure 11A). This mutation has been described by Stenzinger and collegues 
(2014), but has not been included in any databases, such as the COSMIC database and 
Ensemble. The third mutation consists of a nonsynonymous substitution of a cytosine for 
a thymine (transition, c.1376C>T) in the second position of codon 459 (TCT  TTT), 
resulting in a nonconservative substituition of a Serine for a Phenylalanine, p.Ser459Phe 
(figure 11B). This mutation has been described as a mutation hotspot by Briggs and 
Tomlinson (2013) and in the COSMIC database. The first mutation, the p.Pro286Arg in 
exon 9, was found in one case (T286) and, interestingly, the other two mutations, the 
p.Asp301Asn and the p.Ser459Phe in exons 9 and 14, respectively, were found in the 
same tumor (T368). 
In order to determine the somatic or germline nature of the mutations found in the 
tumor tissues, we analyzed DNA samples extracted from normal mucosa adjacent to the 
tumor, and none of the mutations found in the tumors were present in normal cells of the 
patients (figures 10 and 11, right panels), indicating that all the mutations found are 
somatic. 
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Figure 10 - DNA sequence electropherograms obtained from the tumor T286 (left) with the mutation POLE 
c.857C>G, p.Pro286Arg, and from the normal adjacent mucosa (right).  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 - DNA sequence electropherograms obtained from tumor T368 (left) with the mutations (A) POLE 
c.901G>A, p.Asp301Asn, and (B) POLE c.1376C>T, p.Ser459Phe. Normal adjacent mucosa sequences are 
shown to the right.  
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Besides these mutations, we have also found one synonymous variant in exon 13 
in two cases, the c.1347G>A (p.=), already described in the literature as a polymorphism 
(rs142373951). Moreover, another synonymous variant, the c.1467C>T (p.=) not 
described in any database, was found in exon 14 in one case.  
 
2. Clinicopathological characteristics  
 
Case T286, with the mutation POLE c.857C>G, p.Pro286Arg, was a man who was 
diagnosed at age 28 years with a moderately differentiated ascending colon 
adenocarcinoma. Histopathologically, the tumor presented a cribiform pattern and, 
according to the TNM classification, the tumor stage was pT4NxMx. A right 
hemicolectomy was performed, and he was treated with FOLFIRI and cetuximab and died 
a year after diagnosis. The patient's tumor was previously tested for mutations in exons 2, 
3 and 4 of the KRAS and NRAS genes, and exon 9 and 20 of the PIK3CA gene. The 
tumor did not present any mutations in KRAS and NRAS, but showed a mutation in exon 
9 of PIK3CA, the c.1624G>A, p.Glu542Lys. 
Case T368, with the mutations POLE c.901G>A, p.Asp301Asn, and the 
c.1376C>T, p.Ser459Phe, was a man who was diagnosed at age 49 years with mucinous 
adenocarcinoma located in the cecum, invading the muscle layer. The remaining mucosa 
had tubular adenomatous polyps with low-grade dysplasia. The adenocarcinoma was well 
differentiated and, according to the TNM classification, the patient had stage and grade I 
disease (pT2N0M0). The patient underwent a right hemicolectomy and, two years later, 
had a pelvic recurrence compatible with a primary tumor of the colon. The patient was 
treated with FOLFOX as a first-line treatment, the second-line treatment was leucoverin 
and 5-FU, and the third-line was FOLFIRI and cetuximab; the patient died three years 
later. At the time of therapeutic decision, this tumor only had been studied for mutations in 
exon 2 of KRAS. After treatment, this tumor was also studied for exons 3 and 4 of KRAS 
and exons 2, 3 and 4 of NRAS, and the tumor presented a mutation in exon 4 of KRAS, 
the c.351A>C, p.Lys117Asn. 
These clinicopathologic characteristics are summarized in table 5. 
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Table 5 - Clinicopathologic features, BRAF, KRAS and PIK3CA mutation status, immunohistochemistry of MMR protein and microsatellite instability status in the tumors with 
POLE mutations. 
 
 
 
MMR - Mismatch repair; IHC: immunohistochemistry; MSI: microsatellite instability; MSI-L: microsatellite instability-low; MSS: microsatellite stable 
 
 
Tumor 
sample 
Differentiation Localization Stage 
Age of 
diagnosis 
POLE 
BRAF 
p.Val600Glu 
KRAS PIK3CA 
IHC 
MMR 
MSI 
T286 Moderately 
Ascending 
Colon 
pT4NxMx 28 
c.857C>G,  
p.Pro286Arg 
Wild type Wild type 
 
c.1624G>A, 
p.Glu542Lys 
Normal MSI-L 
           
T368 Well Cecum pT2N0M0 49 
c.901G>A,  
p.Asp301Asn, 
and c.1376C>T,  
p.Ser459Phe 
Wild type 
c.351A>C,  
p.Lys117Asn 
Wild type Normal MSS 
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3. Microsatellite instability analysis  
 
The two cases with POLE mutations were studied by immunohistochemistry and 
both showed normal expression of MMR proteins. They were also evaluated for MSI, and 
the tumor with the mutation POLE c.857C>G, p.Pro286Arg, displayed instability only at 
the BAT25 locus (figure 12A), being therefore classified as MSI-L. The tumor with the two 
POLE mutations c.901G>A, p.Asp301Asn, and c.1376C>T, p.Ser459Phe, did not exhibit 
any alteration in the five markers, and it was consequently classified as MSS (figure 12B). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 - Fragment analysis electropherograms showing the BAT25 microsatellite marker; (A) Tumor 
sample T286 exhibited microsatellite instability in this marker; (B) Tumor sample T368 does not display 
microsatellite instability in this marker.  
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4. BRAF p.Val600Glu analysis 
 
The BRAF p.Val600Glu mutation was analyzed by HRM followed by SNuPE in the 
two cases with POLE mutations. This BRAF mutation was not detected in any of the 
cases (figure 13). 
 
 
  
B 
A 
c.1799T>A 
c.1799A 
c.1798G 
c.1800C 
c.1799T 
c.1799A>T 
c.1798G 
c.1800C 
B 
A 
Figure 13 - Electropherograms from the BRAF Single nucleotide primer extension (SNuPE) analyses for tumor 
sample T286 (A) and positive control for the BRAF p.Val600Glu mutation (B). The first peak corresponds to 
position 1799 reverse, the second corresponds to position 1798 forward, the third corresponds to position 
1800 reverse and the last peak corresponds to position 1799 forward. 
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V. Discussion 
 
Several decades of CRC research have revealed that this disease cannot be 
viewed as one cancer entity, but comprises distinct molecular tumor subtypes. 
Nevertheless, the biological characteristics of CRC are not yet completely defined. 
Recently, the TCGA project (2012) discovered that recurrent somatic POLE EDMs occur 
in approximately 3% of sporadic CRCs and Palles and collaborators, in 2013, found a 
subset of MSS CRC patients that harbor germline POLE EDMs. POLE has an essential 
role in chromosomal DNA replication, namely in the leading-strand synthesis (Pursell et 
al., 2007). It also has an important function in the recognition and removal of mispaired 
nucleotides by its proofreading capacity through the POLE exonuclease domain, crucial 
for the maintenance of replication fidelity (Palles et al. 2013). Some authors studied the 
effect of mutations in POLE using yeast, since the yeast POLE construct was shown to 
have identical replication fidelity to the POLE enzyme and it is therefore a useful substitute 
for in vitro replication fidelity assays (Pursell et al., 2007; Shinbrot et al., 2014). The amino 
acid substitutions in the POLE exonuclease domain had only marginal effects on DNA 
polymerase function, but each mutation dramatically reduced 3’-5’ exonuclease activity 
comparative to the wild-type POLE (Miyabe et al., 2011; Shinbrot et al., 2014). We found 
three POLE EDMs, the c.857C>G, p.Pro286Arg, the c.901G>A p.Asp301Asn, and the 
c.1376C>T p.Ser459Phe. 
The p.Pro286Arg mutation found in tumor T286 was previously reported as the 
most common somatic hotspot mutation in POLE (Briggs and Tomlinson, 2013). The 
aminoacid Pro286 is located in the DNA binding pocket adjacent to the exonuclease 
active site, in the end of the Exo I motif (residues 271-285; figure 14), with its side chain 
very close to the nascent single-stranded DNA. Substitution by an Arginine at this residue 
is predicted to significantly perturb the structure of the DNA binding pocket and, 
consequently, to have a significant effect on protein function. Mutation in the equivalent 
residue of T4 bacteriophage produces a strong mutator phenotype, which confirms this 
hypothesis (Palles et al. 2013; Briggs and Tomlinson, 2013). In yeast, this variant confers 
fidelity defects well beyond those expected from proofreading deficiency, shows an 
exceptionally strong mutator effect and increased chances of accumulating cancer-driving 
mutations (Kane and Shcherbakova, 2014). Interestingly, Kane and Shcherbakova found 
this variant in a tumor from a 54-year-old individual, a relatively early cancer onset 
compared with the median age at diagnosis in their group of patients (69 years) (Kane 
and Shcherbakova, 2014). This is in agreement with our results, since this mutation was 
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found in a tumor from a 28-year-old individual (the median age at diagnosis in our series 
was 59), diagnosed with a tumor in stage T4.  
The p.Asp301Asn mutation found in tumor T368 was previously described by 
Stenzinger and colleagues (2014) in only one tumor and has not been reported in any 
database. However, Stenzinger and coworkers studied the biological impact of the 
mutations in silico, and this mutation was classified as harmful by all four softwares used 
(mutationTaster, PolyPhen, PROVEAN and SIFT) (Stenzinger et al., 2014). The 
aminoacid Asp301 is located in the end of the Exo I motif, so the substitution by an 
Asparagine has probably a negative effect on the proofreading function (figure 14) 
(Henninger and Pursell 2014).  
The p.Ser459Phe mutation found in tumor T368 was previously reported as a 
somatic mutation hotspot (Briggs and Tomlinson, 2013). The aminoacid Pro459 is 
localized in the Exo III motif (figure 14). This aminoacid was found in secondary structural 
elements that might support single-stranded DNA binding and/or catalysis and the 
substitution by a Phenylalanine reduce proofreading activity (Henninger and Pursell 2014; 
Shinbrot et al., 2014). 
Interestingly, the POLE p.Asp301Asn and p.Ser459Phe mutations were found in 
the same tumor. It was not possible to clarify whether these mutations were present in the 
same clone (in cis or in trans) or in different clones, being therefore unknown if the two 
mutations occurred simultaneously, if the presence of one mutation resulted in another 
mutation in the same clone, or if these mutations in the same tumor are an example of 
intratumor heterogeneity.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 - The structure of POLE demonstrating the position of the POLE somatic mutations that we found in 
our series. The mutations underlined were found in the same tumor, T368. Conserved exo motifs I–V within 
the exonuclease domain are highlighted in blue. The polymerase domain and zinc finger are represented in 
yellow and orange, respectively. 
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The TCGA project divided tumors into non-hypermutated (defined as <8.24 per 106 
bases) and hypermutated (defined as >12 mutations per 106 bases) cancers (Cancer 
Genome Atlas Network, 2012). The non-hypermutated group had significantly more gene 
copy number alterations, TP53 or APC mutations, which characterizes CIN tumors 
(Carethers and Jung, 2015; Deb and Fox, 2014; Sanz-García et al., 2014). The 
hypermutated tumors are separated into hypermutated with microsatellite instability and 
CIMP, or hypermutated without microsatellite instability with somatic mutations in related 
DNA repair genes, such as POLE (Akkad et al., 2015; Cancer Genome Atlas Network, 
2012; Carethers and Jung, 2015). In our study we observed that the tumor T286 was MSI-
L, with just one positive marker, and the tumor T368 was MSS, with these data being in 
agreement with those reported by the TCGA project. It is therefore likely that CRCs with 
POLE EDMs define a hypermutated and MSS or MSI-L group of tumors (Cancer Genome 
Atlas Network, 2012). However, it is not yet known if this group of tumors follows one of 
the previous established subtypes of CRC pathways or if they represent a new 
pathogenetic pathway. 
The “ultramutated” phenotype is associated with loss of the POLE proofreading 
function and, according to the literature, these tumors with POLE EDMs present high 
mutational burden in the known CRC driver genes. However, these mutations in CRC 
driver genes are often of types and at positions other than the common hotspots in those 
genes (Heitzer and Tomlinson, 2014). In our study, we observed that none of the two 
POLE positive tumors presented the BRAF p.Val600Glu mutation, but study of KRAS and 
NRAS (exon 2, 3 and 4) and PIK3CA (exon 9 and 20) showed that tumor T286 exhibited 
the p.Glu542Lys PIK3CA mutation and tumor T368 displayed the p.Lys117Asn KRAS 
mutation. Both mutations are outside the most common hotspots in these genes, which is 
in agreement with the literature (Heitzer and Tomlinson, 2014). These mutations might be 
functionally suboptimal with respect to the “classical” mutations, such as those at KRAS 
codons 12 and 13. Nevertheless, they are tolerated because the ultramutator cancer can 
quickly acquire additional advantageous mutations (Heitzer and Tomlinson, 2014). 
Hypermutation is thus a very plausible consequence of POLE EDMs, but it remains 
unclear if this is the only tumor-promoting consequence of these mutations, and more 
studies are needed to better understand the role of POLE mutation in the colorectal 
carcinogenesis. 
The two cases with POLE mutations were advanced colorectal tumors, and the 
patient with tumor T286, harboring the POLE p.Pro286Arg mutation, was diagnosed in 
stage T4 and died one year after diagnosis. In spite of the apparent poor prognosis in 
these patients, we cannot assess if POLE mutations have prognostic or predictive 
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implications due to the small number of mutations found. Nevertheless, Stenzinger and 
collaborators demonstrated that patients with stage III/IV tumors harboring POLE 
mutations had a statistically significant increased mortality and speculated that certain 
chemotherapeutic agents may increase the probability of tumors harboring POLE 
mutations gain additional genetic alterations, which in turn may confer a more malignant 
genotype and subsequent phenotype (Stenzinger et al., 2014). On the other hand, 
preliminary data suggested that patients with POLE mutant ECs have significantly better 
outcomes, and therefore may require less aggressive treatment (Cancer Genome Atlas 
Network, 2013; Church et al., 2015; Meng et al., 2014). This favorable outcome was 
explained by the extreme genetic instability in tumors with this ultramutator phenotype, 
making them unable to deal with DNA damage induced by cytotoxic treatment (Heitzer 
and Tomlinson 2014). It is unclear how the same pathogenetic mechanism would drive 
opposite prognosis in the different tumor types, so further studies are necessary to 
comprehend the biological impact of these mutations in mCRC and other malignancies. 
We identified a lower frequency of somatic POLE mutations (0.65%) compared to 
previous reports in the literature (3-12.3%) (Cancer Genome Atlas Network, 2012; 
Stenzinger et al., 2014). The selection criteria could explain the differences between 
frequencies of somatic POLE EDMs observed. While our series were composed by a 
consecutive series of advanced colorectal tumors not selected for MSI status, the series 
described by Stenzinger and co-workers (2014) consisted of CRCs with MSS phenotype, 
increasing the frequency of somatic POLE mutations since these mutations were mostly 
found in MSS tumors. However, the patient selection based on stage seems to be less 
relevant, since Stenzinger and co-workers (2014) found 11 POLE EDMs in 66 stage I 
tumors (17%), 13 POLE EDMs in 118 stage II tumors (11%), 13 POLE EDMs in 129 stage 
III tumors (10%), and nine POLE EDMs in 55 stage IV tumors (16%), revealing no 
associations between POLE EDMs and tumor stage. This indicates that POLE EDMs can 
be early events during colorectal carcinogenesis and are not merely the result of tumor 
genetic progression. 
The authors of the TCGA project highlighted mutations in POLE as important 
somatic changes, but the consequences of POLE EDMs are not yet completely defined. 
Alterations of proofreading function may be selectively deleterious for the cell, so it would 
also be important to determine whether proofreading deficiency has any effect on 
polymerase processivity. Therefore, it is tempting to speculate whether EDMs in POLE 
have prognostic or predictive implications and subsequently further studies will be needed 
to understand how these mutations contribute to carcinogenesis and their clinical 
implications (Briggs and Tomlinson, 2013; Heitzer and Tomlinson, 2014). Furthermore, 
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similarly to other examples of targeted therapy based on deficient DNA repair 
mechanisms (Livraghi and Garber, 2015), it would be important to explore how the 
hypermutated phenotype associated with POLE mutations can be used therapeutically, 
especially in the context of advanced CRC. 
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VI. Future perspectives 
 
The tumors with POLE EDMs present an “ultramutated” phenotype, so it is 
extremely important to perform a detailed molecular characterization of these tumors. We 
would like to analyze a panel of genes involved in colorectal carcinogenesis through next-
generation sequencing, in order to compare mutational profiles of tumors with POLE 
mutations, normal colon mucosa, and representative tumor samples of previous 
established molecular subtypes (CIN, MSI and CIMP). This characterization will allow a 
better understanding of the role of POLE mutations in advanced colorectal cancers, to find 
out whether these tumors follow a different pathway, and to explore how this 
hypermutated phenotype can be explored therapeutically. 
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